The main objective of this trial is to establish the bioequivalence of survodutide in a pre-filled syringe (reference product \[formulation A\]) and in a vial (test product \[formulation B2\]) in male and female trial participants who are healthy or otherwise healthy with overweight/obesity, following subcutaneous administration.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
44
Pre-filled pen
Survodutide formulation B2
hVIVO Mannheim
Mannheim, Germany
RECRUITINGArea under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Time frame: Up to Day 22
Maximum measured concentration of the analyte in plasma (Cmax)
Time frame: Up to Day 22
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: Up to Day 22
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.